Cylaina E. Bird
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cylaina E. Bird has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Joseph Buehler
Emory University School of Medicine
1 shared publication - Kalil G. Abdullah
Department of Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
1 shared publication - Kimmo J. Hatanpaa
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, USA
1 shared publication Lauren C. Gattie
Department of Neurological Surgery, University of Texas Southwestern Medical Center
1 shared publicationMichael M. Levitt
Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center
1 shared publication- Milan R. Savani
Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA
1 shared publication
Latest Publications
- Open Access
Semi-automated computational assessment of cancer organoid viability using rapid live-cell microscopy
The creation of patient-derived cancer organoids represents a key advance in preclinical modeling and has recently been applied to a variety of human solid tumor types. However, conventional methods used to assess cellular viability in tissue specimens are poorly suited for the evaluation of cancer organoids because they are time-intensive and involve tissue destruction. To address this issue, we established a suite of 3-dimensional patient-derived glioma organoids, treated them with chemoradiotherapy, stained organoids with non-toxic cell dyes, and imaged them using a rapid laser scanning confocal microscopy method termed “Apex Imaging”. We then developed and tested a fragmentation algorithm to quantify heterogeneity in the topography of the organoids as a potential surrogate marker of viability. This algorithm, SSDquant, provides a 3-dimensional visual representation of the organoid surface and a numerical measurement of the sum-squared distance (SSD) from the derived mass center of the organoid. We tested whether SSD scores correlate with traditional immunohistochemistry-derived cell viability markers (cellularity and cleaved caspase 3 expression) and observed statistically significant associations between them using linear regression analysis. Our work describes a quantitative, non-invasive approach for the serial measurement of patient-derived cancer organoid viability, thus opening new avenues for the application of these models to studies of cancer biology and therapy.
Open AccessSemi-automated computational assessment of cancer organoid viability using rapid live-cell microscopy
The creation of patient-derived cancer organoids represents a key advance in preclinical modeling and has recently been applied to a variety of human solid tumor types. However, conventional methods used to assess cellular viability in tissue specimens are poorly suited for the evaluation of cancer organoids because they are time-intensive and involve tissue destruction. To address this issue, we established a suite of 3-dimensional patient-derived glioma organoids, treated them with chemoradiotherapy, stained organoids with non-toxic cell dyes, and imaged them using a rapid laser scanning confocal microscopy method termed “Apex Imaging”. We then developed and tested a fragmentation algorithm to quantify heterogeneity in the topography of the organoids as a potential surrogate marker of viability. This algorithm, SSDquant, provides a 3-dimensional visual representation of the organoid surface and a numerical measurement of the sum-squared distance (SSD) from the derived mass center of the organoid. We tested whether SSD scores correlate with traditional immunohistochemistry-derived cell viability markers (cellularity and cleaved caspase 3 expression) and observed statistically significant associations between them using linear regression analysis. Our work describes a quantitative, non-invasive approach for the serial measurement of patient-derived cancer organoid viability, thus opening new avenues for the application of these models to studies of cancer biology and therapy.